Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18509061 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Wang S, et al. (2008) Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A 105, 7738-43 18509061
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S246-p - HDAC4 (human) ▲
Orthologous residues
HDAC4 (human): S246‑p, HDAC4 (mouse): S245‑p, HDAC4 (rat): S245‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6976 VEGF inhibit treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase

S467-p - HDAC4 (human) ▲
Orthologous residues
HDAC4 (human): S467‑p, HDAC4 (mouse): S465‑p, HDAC4 (rat): S466‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6976 VEGF inhibit treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase

S632-p - HDAC4 (human) ▲
Orthologous residues
HDAC4 (human): S632‑p, HDAC4 (mouse): S629‑p, HDAC4 (rat): S630‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6976 VEGF inhibit treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase

S259-p - HDAC5 (human) ▲
Orthologous residues
HDAC5 (human): S259‑p, HDAC5 (mouse): S250‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6976 VEGF inhibit treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase

S498-p - HDAC5 (human) ▲
Orthologous residues
HDAC5 (human): S498‑p, HDAC5 (mouse): S488‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6976 VEGF inhibit treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase

S155-p - HDAC7 (human) ▲
Orthologous residues
HDAC7 (human): S155‑p, HDAC7 (mouse): S178‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKD1 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, transfection of constitutively active enzyme, mutation in upstream enzyme recognition motif, co-immunoprecipitation, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6983 VEGF inhibit treatment-induced increase
Go 6976 VEGF inhibit treatment-induced increase
BAPTA-AM VEGF no effect upon treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase
siRNA VEGF PKD1 (human) inhibit treatment-induced increase
IGF-1 increase
TGF-beta increase
endothelin increase
aFGF increase
apelin no change compared to control
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Effect of modification (process):  cell growth, altered, cell motility, altered
 Comments:  nucleo-cytoplasmic shuttling

S358-p - HDAC7 (human) ▲
Orthologous residues
HDAC7 (human): S358‑p, HDAC7 (mouse): S344‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKD1 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, transfection of constitutively active enzyme, mutation in upstream enzyme recognition motif, co-immunoprecipitation, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6983 VEGF inhibit treatment-induced increase
Go 6976 VEGF inhibit treatment-induced increase
BAPTA-AM VEGF no effect upon treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase
siRNA VEGF PKD1 (human) inhibit treatment-induced increase
IGF-1 increase
TGF-beta increase
endothelin increase
aFGF increase
apelin no change compared to control
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Effect of modification (process):  cell growth, altered, cell motility, altered
 Comments:  nucleo-cytoplasmic shuttling

S486-p - HDAC7 (human) ▲
Orthologous residues
HDAC7 (human): S486‑p, HDAC7 (mouse): S479‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKD1 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, transfection of constitutively active enzyme, mutation in upstream enzyme recognition motif, co-immunoprecipitation, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6983 VEGF inhibit treatment-induced increase
Go 6976 VEGF inhibit treatment-induced increase
BAPTA-AM VEGF no effect upon treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase
siRNA VEGF PKD1 (human) inhibit treatment-induced increase
IGF-1 increase
TGF-beta increase
endothelin increase
aFGF increase
apelin no change compared to control
Downstream Regulation
 Effect of modification (function):  intracellular localization
 Effect of modification (process):  cell growth, altered, cell motility, altered
 Comments:  nucleo-cytoplasmic shuttling

S220-p - HDAC9 iso5 (human) ▲
Orthologous residues
HDAC9 (human): S220‑p, HDAC9 iso5 (human): S220‑p, HDAC9 iso6 (human): ‑, HDAC9 (mouse): S220‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6976 VEGF inhibit treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase

S451-p - HDAC9 iso5 (human) ▲
Orthologous residues
HDAC9 (human): S451‑p, HDAC9 iso5 (human): S451‑p, HDAC9 iso6 (human): S410‑p, HDAC9 (mouse): S450‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  HAEC (endothelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
Go 6976 VEGF inhibit treatment-induced increase
KN-93 VEGF no effect upon treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.